[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.98.119. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
June 1999

Prognostic Factors in Leukocytoclastic Vasculitis: What Is the Role of Antineutrophil Cytoplasmic Antibody?

Author Affiliations

Not Available

Arch Dermatol. 1999;135(6):714-a-715. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-6-dlt0699

We read with interest the article of Sais et al1 in a recent issue of the ARCHIVES that reports on an investigation into risk factors for systemic involvement in cutaneous leukocytoclastic vasculitis (CLV) and the probability of its long-term course. We believe that some basic difficulties exist in identifying the prognostic factors in CLV. The first is the potential association with a certain number of systemic diseases and factors that we are aware of and others that we still do not know. The second is the variable level of activity of CLV in chronic forms, which is often not related to the activity of the associated condition. The third is the interference of previous or present medications.

First Page Preview View Large
First page PDF preview
First page PDF preview
×